Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma

Next Previous
X
Search
Trial Profile

A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Clear cell sarcoma; Gastrointestinal stromal tumours; Leiomyosarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 05 Dec 2022 Planned End Date changed from 16 Oct 2022 to 16 Oct 2023.
    • 09 Nov 2021 Planned End Date changed from 30 Sep 2021 to 16 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top